Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Next Previous
Trial Profile

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desoximetasone (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacodynamics
  • Sponsors Taro Pharmaceuticals USA

Most Recent Events

  • 21 Apr 2020 Status changed from recruiting to completed.
  • 08 Apr 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
  • 26 Jan 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top